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ABSTRACT
Migraine involves brain hypersensitivity with
episodic dysfunction triggered by behavioral or
physiological stressors. During an acute
migraine attack the trigeminal nerve is activated (peripheral sensitization). This leads to
central sensitization with activation of the
central pathways including the trigeminal
nucleus caudalis, the trigemino-thalamic tract,
and the thalamus. In episodic migraine the
sensitization process ends with the individual
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act, but with chronic migraine central sensitization may continue interictally. Increased
allostatic load, the consequence of chronic,
repeated exposure to stressors, leads to central
sensitization, lowering the threshold for future
neuronal activation (hypervigilance). Ostensibly innocuous stressors are then sufficient to
trigger an attack. Medications that reduce sensitization may help patients who are hypervigilant and help to balance allostatic load. Acute
treatments and drugs for migraine prevention
have traditionally been used to reduce attack
duration and frequency. However, since many
patients do not fully respond, an unmet treatment need remains. Calcitonin gene-related
peptide (CGRP) is a vasoactive neuropeptide
involved in nociception and in the sensitization
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of peripheral and central neurons of the
trigeminovascular system, which is implicated
in migraine pathophysiology. Elevated CGRP
levels are associated with dysregulated signaling
in the trigeminovascular system, leading to
maladaptive responses to behavioral or physiological stressors. CGRP may, therefore, play a
key role in the underlying pathophysiology of
migraine. Increased understanding of the role of
CGRP in migraine led to the development of
small-molecule antagonists (gepants) and
monoclonal antibodies (mAbs) that target
either CGRP or the receptor (CGRP-R) to restore
homeostasis, reducing the frequency, duration,
and severity of attacks. In clinical trials, US Food
and Drug Administration-approved anti-CGRPR/CGRP mAbs were well tolerated and effective
as preventive migraine treatments. Here, we
explore the role of CGRP in migraine pathophysiology and the use of gepants or mAbs to
suppress CGRP-R signaling via inhibition of the
CGRP ligand or receptor.
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cells, is important in migraine pathophysiology. CGRP binds smooth muscle cell receptors,
dilating blood vessels supplying the brain, and
also binds to peripheral nerve cells that transmit pain signals to the spinal cord and brain.
CGRP levels are elevated during a migraine
attack. Medications targeting the CGRP pathway may decrease sensitivity and potentially
normalize responses in hypervigilant patients.
Two commercially available oral drugs that
block CGRP receptors (‘gepants’) have reduced
symptoms during migraine attacks in clinical
trials. Four monoclonal antibodies (proteins
that bind a specific molecule) have also been
developed that target CGRP or the receptor and
have been shown to significantly reduce the
number of migraine days per month.

Keywords: Allostatic load; Calcitonin generelated peptide; CGRP; CGRP-R; CGRP
receptor;
Hypervigilance;
Migraine;
Monoclonal antibody; Treatment
Key Summary Points

PLAIN LANGUAGE SUMMARY
Migraine is a neurological disease affecting one
in eight people. Symptoms include nausea and/
or sensitivity to light and sound, and a throbbing headache. Although certain genes may
increase the likelihood of migraine, environmental stimuli and molecules that increase the
sensitivity of brain blood vessels and their
innervations also play a role. During a migraine
attack, nerves in the brain are activated, leading
to increased sensitivity to stimuli, lowering the
future threshold for activation, and making
patients hypervigilant. Chronic, repeated
exposure to certain stimuli can also lower this
activation threshold, such that relatively
innocuous stimuli can trigger an attack. Excessive use of certain migraine treatments can
increase headache frequency over time and
produce unwanted side effects; thus, selective
agents are needed that specifically target the
systems and pathways affected in migraine
pathophysiology. Calcitonin gene-related peptide (CGRP), produced and released by nerve

Migraine is a common neurological
disorder affecting approximately 14% of
the population. There is an unmet need
for new therapeutics because many
patients do not respond to treatment.
Calcitonin gene-related peptide (CGRP)
plays a key role in migraine pathogenesis,
and recent therapeutic advances are based
around targeting CGRP or its canonical
receptor (CGRP-R).
Individuals affected by migraine have a
reduced threshold for central
sensitization: this is known as
hypervigilance. The combination of
central sensitization and migraine triggers
(allostatic load) results in migraine
attacks. Repeated migraine attacks, which
involve the release of CGRP to facilitate
peripheral and central sensitization,
probably contribute to increased allostatic
load.
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In this review, the evidence supporting the
role of CGRP in migraine is evaluated,
including its role in the sensitization of
peripheral and central neurons of the
trigeminovascular system as well as its
implication for hypervigilance and
allostatic load.
By inhibiting the release of proinflammatory molecules within the
trigeminal ganglion and/or the dura and,
therefore, reducing peripheral
sensitization, anti-CGRP monoclonal
antibodies (mAbs) might indirectly
diminish central sensitization, reduce
allostatic load, and contribute to migraine
regression.
Use of anti-CGRP and anti-CGRP-R mAbs
for the treatment of migraine is
promising. A summary of the latest mAb
clinical trials and real-world data provides
an overview of the therapeutic landscape,
including erenumab-aooe, galcanezumabgnlm, fremanezumab-vfrm, and
eptinezumab-jjmr, which are approved by
the US Food and Drug Administration
(FDA) for the preventive treatment of
migraine.
An update is also provided on clinical
trials involving small-molecule CGRP
receptor antagonists known as gepants,
including ubrogepant and rimegepant,
which were recently approved by the FDA
for the acute treatment of migraine with
or without aura in adults, and two
additional therapeutic candidates
(atogepant and zavegepant [formerly
vazegepant]), which remain in
development.

INTERACTIVE INFOGRAPHIC
This article contains an interactive infographic
to help to illustrate the role of CGRP in
migraine. To view it, click here: https://go.sn.
pub/tsAHdE.
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DIGITAL FEATURES
This article is published with digital features,
including a plain language summary, key summary points, interactive infographic, and video
to facilitate understanding of the article. To
view digital features for this article go to https://
doi.org/10.6084/m9.figshare.14061551.

INTRODUCTION
Migraine is among the most disabling disorders
globally; in 2016, an estimated 1 billion people
were affected [1]. The global age-standardized
prevalence was approximately 14%, with
approximately twice as many women than men
being affected [1]. Estimates in the USA indicate
an annual cost of approximately $36 billion
[2–4]. Prevalence increases between the ages of 12
and 40 years and accounts for at least 1 day of
school or work lost every 3 months among up to
one-third of individuals [2, 4]. Social perceptions
of migraine mean that patients may be dismissed
as not having a serious disease. This perception is
shared by some physicians [5], which exacerbates
the significant negative impact migraine has on
patients’ quality of life and ability to work [6].
Migraine features include moderate-to-severe
throbbing headache, nausea and/or vomiting,
and hypersensitivity to light and noise [7]. There
is an important and complex genetic component
to the disorder, but it remains unclear which
genes and loci are implicated in its pathogenesis
[8]. Migraine may be triggered by stress [9],
exposure to bright light [9], pungent or strong
odors [10], and barometric pressure changes [11].
Prodromal symptoms (e.g., fatigue, irritability,
difficulty concentrating, mood change, yawning, stiff neck, phonophobia, and nausea) and
postdromal symptoms (e.g., tiredness, weakness,
cognitive difficulties, and mood change) are
characteristic [12]. Migraine is classified as either
episodic migraine (EM; \ 15 days of headache
per month) or chronic migraine (CM;
for [ 3 months, headache for C 15 days per
month with features of a migraine headache
on C 8 days per month) [13, 14].
Acute migraine management aims to reduce
pain and symptoms and to restore physical and
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psychosocial function [6]. Possibly owing to a
lack of adequate preventive treatments, acute
therapies are frequently overused, which can
lead to medication-overuse headache. Therefore, attempts are made to limit use of these
treatments to 2–3 days per week [15]. Preventive
migraine therapies are used for patients who
have frequent and/or debilitating attacks, in
whom acute medication fails to provide relief,
or in whom there is a risk of overuse of acute
medication [15]. The goals of preventive therapies are to reduce migraine frequency, duration,
and/or severity of attacks, to improve responsiveness to acute therapy, to decrease use of
acute therapy, and to increase the patient’s
functional ability [16].
Traditional preventive therapies for migraine
are inadequate, with up to 86% of patients discontinuing treatment early [17–19]. A retrospective US claims analysis shows that
persistence with oral migraine preventive medications decreases over time, with only 14% of
patients remaining on initial preventive treatment at 12 months [18]. Additionally, in a USbased survey, 39% of patients with migraine
reported that they had used preventive medication at some time, with only 12% indicating
that they were current users [20]. Thus, there
remains a considerable unmet need for efficacious, well-tolerated preventive therapies with
low potential for side effects.
The neuropeptide calcitonin gene-related
peptide (CGRP) is a vasodilator with multiple sites
of action that is involved in nociception and
sensitization of peripheral and central neurons in
the trigeminovascular system, which is implicated in migraine pathophysiology [7, 21–24].
Levels of CGRP in jugular venous blood and
cerebrospinal fluid are elevated in patients with
CM or EM [25–27], and these levels fall as migraine
pain subsides upon triptan treatment, supporting
a relationship between CGRP and migraine [28].
In rodents, application of CGRP to the cranial
meninges triggered migraine-like signs of allodynia and pain in females but not in males: this
hypersensitivity may contribute to the higher
prevalence of migraine in females [29]. The
involvement of CGRP in migraine has been substantiated by preclinical and clinical trials of drugs
that block the activity of CGRP [30–34].
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Additionally, CGRP infusion can trigger an attack
in susceptible patients who experience migraine
[35]. This review explores the role of CGRP in
migraine, including its involvement in allostatic
overload (i.e., when the beneficial acute stress
response to external stimuli becomes maladaptive
owing to chronic exposure to stressors) [36] and
the use of monoclonal antibodies (mAbs) that
suppress CGRP receptor (CGRP-R) signaling,
potentially rebalancing allostatic load (Fig. 1).
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.

MIGRAINE PATHOPHYSIOLOGY
Migraine consists of distinct phases; in * 30%
of patients it may be associated with aura (visual, sensory, motor, and language or brain
stem disturbances) [37, 38]. Phases include the
prodromal phase, probably mediated by the
hypothalamus with multiple neurotransmitters
believed to be involved (e.g., serotonin, orexin)
and a potential aura phase, associated with a
slow wave of neural depolarization called cortical spreading depression (CSD) that may activate trigeminal afferents (although the precise
mechanism is unknown) [9, 12]. These are followed by the headache phase, which is mediated by activation of the trigeminovascular
system, and the postdromal phase, which is
associated with hyperperfusion in patients with
aura and with bilateral posterior cortical
hypoperfusion that persists after treatment in
patients without aura [12]. The final (interictal)
phase is characterized by reduced activation of
the spinal trigeminal nuclei (Fig. 2) [9].
CSD is associated with an increase in proinflammatory molecules and neuropeptides,
including CGRP, and can activate the trigeminovascular system [39, 40]. The relationship
between CSD and CGRP may be a contributory
factor in migraine [39]. Drugs targeting CGRP-R
signaling, including mAbs, reduce the activation of trigeminovascular neurons by CSD
[41, 42].
Migraine is regarded as a neurovascular disease, driven by both neurovascular changes and

Neurol Ther (2021) 10:469–497
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Fig. 1 Role of CGRP in migraine. Some individuals have
a genetic predisposition to hypervigilance, thus having a
heightened awareness of sensory stimuli, which may have
provided an evolutionary advantage [151]. Association
with too many risk factors leads to increased CGRP levels,
which results in allostatic overload, making individuals
more sensitive to sensory triggers that initiate a migraine

attack [69]. mAbs targeting CGRP or the CGRP-R inhibit
CGRP signaling, potentially rebalancing allostatic load and
reducing the likelihood of a migraine attack. It remains to
be seen if there is a direct effect of anti-CGRP therapeutics
in helping to balance allostatic load. CGRP calcitonin
gene-related peptide, CGRP-R CGRP receptor, mAb
monoclonal antibody

Fig. 2 Migraine phases. Migraine consists of different
phases characterized by physiological changes in the brain
and trigeminovascular system. The headache phase is

associated with activation of the trigeminovascular system
and may last for * 4 to 72 h

modulation of nociceptive input [2]. Activation
of the trigeminovascular system leads to an
inflammatory cascade involving the meninges,
meningeal blood vessels, and subsequent neural
dysfunction (Fig. 3) [37]. The headache phase of

migraine is thought to stem from activation of
nociceptors that innervate the intracranial vasculature [21]. Nociceptive innervation of this
vasculature consists of axons that originate in
the trigeminal ganglion and release vasoactive

Neurol Ther (2021) 10:469–497
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Fig. 3 Components of the trigeminovascular system. The
trigeminovascular system consists of sensory nerves with
their cell bodies in the trigeminal ganglion that innervate
the meningeal blood vessels. Activation of the trigeminovascular system leads to increased release of CGRP and
vasodilation of the meningeal vessels. Pain in the face and

head is primarily mediated by nociceptive afferents of the
ophthalmic division of the trigeminal nerve. Activation of
the meningeal afferents leads to activation of the trigeminal nucleus caudalis and subsequently rostral brain
structures involved in pain perception. CGRP calcitonin
gene-related peptide

neuropeptides such as CGRP and substance P
[21]. Axonal projections of neurons in the
trigeminovascular system transmit nociceptive
signals via second-order neurons in the trigeminal nucleus caudalis and ascending fiber tracts
to nuclei of the brain stem, hypothalamus, and
basal ganglia and are thus potentially relevant
to many symptoms of migraine (e.g., nausea,
vomiting, fatigue, anxiety, and depression).
Furthermore, relay trigeminovascular thalamic
neurons projecting into various regions of the
cortex could account for the location and
intensity of migraine pain as well as transient
symptoms such as clumsiness, loss of concentration and memory, photophobia, and
phonophobia [40]. Perivascular CGRP in the
periphery and central nervous system (CNS)
may therefore act via the vessels innervated by
the trigeminovascular system, the thalamus,
and eventually the cortex to cause migraine
symptoms [2].

CGRP
CGRP is a member of the calcitonin peptide
family, which includes calcitonin, amylin,
adrenomedullin, and adrenomedullin 2/intermedin [43, 44]. There are two human isoforms
of CGRP, a and b, which differ by three amino
acids and share similar biological activities, but
are synthesized from two different genes on
chromosome 11 [45]. CGRP is widely expressed
[22, 33] and is best known for its vasodilatory
effects. Most relevant to its role in the pathophysiology of migraine is its expression in
peripheral components (sensory neurons of
trigeminal and cervical dorsal root ganglia) and
in central components (e.g., parabrachial
nucleus, amygdala, and hypothalamus) [3, 45].
CGRP is primarily expressed in small, unmyelinated sensory C fibers and myelinated Ad fibers
in the peripheral nervous system [22]. In
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contrast to amino acid neurotransmitters,
which act on ionotropic receptors to alter
postsynaptic membrane potentials quickly,
neuropeptides are slower-acting neuromodulators that act through G protein-coupled receptors (GPCRs) [46]. CGRP acts as a modulator of
postsynaptic gain when released from trigeminal nociceptors [46] and indirectly increases
vascular permeability by promoting the release
of substance P [47]. CGRP is stored in axonal
dense core vesicles and can be released from the
axon terminal or along the length of the axon,
unlike neurotransmitters, which are stored in
clear vesicles and released only at the axon terminals. Neuropeptides such as CGRP also differ
from neurotransmitters in that they can function locally or more distally via diffusion in the
vasculature [48].
CGRP Receptors
The calcitonin receptor family comprises two
GPCRs: the calcitonin receptor and the calcitonin-like receptor (CLR). Additional receptor
diversity is provided by heterodimerization of
each of these GPCRs with one of three receptor
activity-modifying proteins (RAMPs), which
modify receptor binding characteristics. The
calcitonin receptor preferentially responds to
calcitonin but also associates with one of the
three RAMPs to form amylin receptors (AMY1–3)
[43]. CLR binds to its ligands (CGRP, adrenomedullin, or adrenomedullin 2) only when associated with RAMPs [43]. Thus, the functional
CGRP-R complex consists of two subunits: CLR
and RAMP1. An additional protein, known as
receptor component protein, can also enhance
signaling by this receptor complex [49].
Although the RAMP1-CLR complex is the CGRPR, recent studies have established that AMY1 acts
as a second CGRP-R and is present in the
trigeminovascular system (Fig. 4) [43, 50, 51].
CGRP-R is expressed on the trigeminal
afferents that project into the meninges; cell
bodies of trigeminal neurons, and satellite glial
cells located in the ganglion; astrocytes and
microglia within the CNS; and mast cells in the
meninges [3, 24]. In cell-based assays, CGRP-R
has high affinity for CGRP and lower affinity for
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other calcitonin family ligands [43]. This
promiscuity in binding within the receptor
family may have important consequences for
therapies targeting CGRP-R signaling [43]. For
example, AMY1 is equally well activated by both
CGRP and amylin and may or may not be
involved in migraine [26, 43]. Furthermore, in
rat trigeminal neurons, CGRP has been shown
to act at AMY1 in addition to CGRP-R, potentially implicating both receptors in CGRP ligand
signal processing [50]. However, to date, a role
for AMY1 in migraine has not been confirmed.
The role of amylin in migraine is unclear, and
an amylin and CGRP head-to-head provocation
study is ongoing (NCT03598075) [52].
CGRP Receptor Signaling Pathway
GPCR signaling in the CGRP-R-mediated pathway is transduced via adenylate cyclase either to
modulate vasodilation in cerebral and meningeal arteries or to transmit nociceptive signals
centrally via the brain stem and midbrain to the
thalamus and higher cortical regions [23].
Activation of CGRP-R may also trigger alternative signaling pathways dependent on the
G proteins and other signaling proteins expressed [26, 53, 54]. Upon ligand binding to CGRPR, the ligand-receptor complex is internalized
into the cell [43, 55, 56]; however, the cell-type
specificity and significance of CGRP-R internalization are not fully understood [43], and cell
signaling may continue once the receptor is
internalized [43, 57]. AMY1 signaling in
response to CGRP and amylin is similar to that
of the CGRP-R, but a recent study suggests that
AMY1 regulation is distinct, because the receptor does not internalize in response to CGRP or
amylin agonists [53, 55, 58, 59].
The action of a ligand can be subject to
functional selectivity at a given receptor
towards a specific signaling pathway (biased
agonism) [60]. Receptor conformations are not
binary; multiple subunit conformations can
exist, and different ligands may stabilize different receptor conformations that interact with
various cellular signaling pathways. Thus, different ligands acting at the same receptor (e.g.,
CGRP or adrenomedullin at the CGRP-R) could

Neurol Ther (2021) 10:469–497
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Fig. 4 The calcitonin receptor family subunit composition. The histograms are indicative of relative ligand
activity upon binding for human receptors. AM adrenomedullin, AM2 adrenomedullin 2, AMY amylin receptor,

CGRP calcitonin gene-related peptide, CLR calcitonin-like
receptor, CT calcitonin, CTR calcitonin receptor, RAMP
receptor activity-modifying protein

activate distinct downstream cellular responses,
a phenomenon not related to their binding
affinity or efficacy [43]. If other ligands prove to
be involved in migraine pathophysiology, this
may have implications for the importance of
targeting the CGRP-R rather than the CGRP
ligand.

CGRP in Migraine
CGRP-Rs are ubiquitous in the smooth muscle
of the vasculature (human middle meningeal,
middle cerebral, pial, and superficial temporal
arteries) and in the trigeminal afferent terminals

Neurol Ther (2021) 10:469–497
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Fig. 5 CGRP receptor and ligand expression sites in the
trigeminovascular system. (a) Localization of the CGRP-R
has been conﬁrmed in the smooth muscle of the
vasculature and in the trigeminal afferents. Some studies
have suggested the CGRP-R may also be present in
macrophages and ﬁbroblasts. (b) CGRP released in the
trigeminal ganglion acts on satellite glia triggering

neurogenic inﬂammation. This initiates peripheral sensitization and, as a result, downstream central sensitization.
(c) CGRP is released at various sites in the trigeminovascular system where it is involved in nociception and
vasodilation. CGRP calcitonin gene-related peptide,
CGRP-R CGRP receptor

(Fig. 5a). CGRP initiates and maintains peripheral and central sensitization by modulating
neurons, glia, and immune cells in the trigeminal pain signaling pathway (Fig. 5b) [3]. During

migraine, CGRP is released at various sites in the
trigeminovascular system, including trigeminal
afferent terminals that innervate the meninges,
trigeminal cell bodies in the ganglion, and
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trigeminal efferent fibers that terminate in the
medulla and cervical spinal cord (Fig. 5c) [3, 24].
At synapses outside the CNS, CGRP causes
vasodilation via receptors on smooth muscle
cells, whereas, at synapses inside the CNS,
CGRP acts on second-order neurons to transmit
pain signals to higher cortical pain regions
[7, 61].
In the dura, CGRP mediates neurogenic
inflammation, immune cell recruitment (such
as mast cells and macrophages), and activation
of sensory neurons; it also activates neurons in
the trigeminal ganglion and signals in a retrograde manner from the spinal cord to neurons
and glia in the trigeminal ganglion, sensitizing
peripheral nociceptors [24, 62–64]. Neuron
activation activates second-order neurons and
glia, which promote central sensitization in the
dorsal horn and spinal trigeminal nucleus caudalis [2, 62].
In sensory neurons within the trigeminal
ganglion, CGRP may increase its expression by a
paracrine mechanism involving release of
proinflammatory mediators from satellite cells
[3, 22]. Although CGRP released in the trigeminal ganglion is unlikely to cross the bloodbrain barrier (BBB), it may influence central
expression of pro-nociceptive compounds and
receptors [24]. Neurotrophic factors such as
brain-derived neurotrophic factor are stimulated by CGRP, which may act to potentiate
central nociceptive neurotransmission [24].
Neurons expressing CGRP project from the
trigeminal ganglion to the trigeminal nucleus
caudalis, where CGRP induces release of glutamate from trigeminal afferents, further facilitating nociception [24]. Together, these effects
provide a mechanism by which drugs acting on
CGRP-R signaling in the peripheral trigeminal
ganglion may modulate both peripheral and
central pain signaling through a peripheral site
of action, highlighting the potential for the use
of these drugs for migraine therapy. It is well
established that when peripheral activation is
switched off, central activation also decreases
[65].
CGRP mediates neuron-glial signaling via
gap junctions within the trigeminal ganglion
[24, 61]. Regional nonsynaptic cross-excitation
occurs within the trigeminal ganglion following
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neuronal and glial activation. This may allow
for coordinated responses to noxious stimuli
that may also, however, sensitize neighboring
neurons [61]. Neuron-glial signaling probably
contributes to peripheral sensitization, which
drives central sensitization [40], facilitating a
lower threshold for neuronal activation in
patients with migraine. Peripheral and central
sensitization in patients may therefore lead to
hypersensitivity to sensory stimuli.
Hypervigilance, Anxiety-Like State,
and Allostatic Overload
Anxiety-like states and a persistent state of
hypervigilance are contributory risk factors for
migraine [66]. Individuals affected by migraine
have a hypervigilant or hyperexcitable nervous
system that is characterized by a lower sensory
activation threshold and hypersensitivity
towards sensory stimuli [67]. The resulting
sensitization and activation of trigeminal
nerves and the nociceptive pathway are
thought to play an important role in the
pathology of migraine [67]. The increased sensitivity to sensory stimuli is caused by a state of
sensory neuron hyperresponsiveness or hyperexcitability, which lowers pain threshold and
tolerance levels [38, 67]. In essence, a state of
hypervigilance is the same as a state of central
sensitization, in which the sensory activation
threshold is reduced.
The role of anxiety and hypervigilance in
migraine may be potentiated by CGRP-R signaling. CGRP promotes sensitization of primary
and secondary trigeminal nociceptive neurons,
leading to an enhanced state of neuronal
excitability [67]. CGRP has also been implicated
in migraine-associated allodynia (a nociceptive
response to normally non-painful stimuli, such
as hair brushing) [67, 68]. Thus, it is possible
that CGRP plays a role in hypervigilance.
Cutaneous allodynia is considered to be a marker of central sensitization and can manifest
both during and between attacks in CM. Brains
of patients with CM remain hyperexcitable in
the interictal phase [69].
Over 50% of people with migraine experience an anxiety disorder over their lifetime [66].
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Infusion with CGRP has been demonstrated to
cause anxiety-like behavior and to induce neuronal activation in the bed nucleus of the stria
terminalis (BNST) [70]. Furthermore, it has been
hypothesized that reciprocal connections
between the BNST and CGRP-containing cells
in the parabrachial nucleus may induce a persistent state of anxiety via positive feedback
[71]. The BNST is continuous with the amygdala
and integrates physiological and behavioral
responses to stress and anxiety by acting as a
relay between limbic structures and the
hypothalamus [3, 72]. Neurons expressing
CGRP in the parabrachial nucleus relay pain
signals from the periphery to the amygdala,
thus encoding the affective component of pain
[73]. In rats, CGRP antagonism has been shown
to suppress grooming and shaking behaviors
induced by CSD, which could indicate that
CGRP is implicated in anxiety and/or pain perception [74].
Migraine is a disorder of allostatic load [75],
triggered by risk factors including stress, sleep
deprivation, light, odors, and noise (Fig. 1).
Allostasis is the body’s ability to respond to
stressful events and it involves hormonal and
neural mediator activation and behavior modification. When behavioral or physiological
stressors become more severe or frequent, the
prolonged exposure dysregulates allostasis,
leading to allostatic overload [76]. Structural
and functional brain networks are altered, and
the responses to stressors become abnormal
[69].
People with migraine have a high allostatic
load, which is more prevalent in EM (50%) than
CM (33%) [75]. Allostatic load is moderate or
high in most patients, and higher than in people without migraine [75]. In migraine, four
main processes are involved in allostatic overload: (1) repeated stress; (2) failure to habituate
to repeated stressors; (3) inability to stop the
stress response normally; and (4) altered stress
response that ultimately leads to compensatory
responses, such as photophobia [69]. Central
sensitization and factors that trigger a migraine
attack both contribute to an individual’s allostatic load and, as sensitization increases, the
need for an attack trigger decreases. Over time,
sensitization levels and exposure to triggers will
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vary within an individual and between individuals [40]. For migraine treatments to be
effective, they need to inhibit or stop persistent
central sensitization.
Migraine may provide an evolutionary
mechanism that enforces a rebalancing of allostatic load in response to a hypersensitive/hypervigilant state, thus relieving hypothalamic
and cortical overload [69]. According to this
model, it may be that CNS-driven changes in
descending inhibitory pain modulation pathways enable more peripheral sensory information to reach the brain via the trigeminalthalamus ascending pain pathway, potentially
improving survival prospects by increasing vigilance, but also increasing allostatic load. CGRP
may play a key role in migraine by increasing
allostatic load mediated by risk factors; therefore, rebalancing CGRP-mediated signaling may
treat or prevent attacks (Fig. 1) [40, 77]. As a key
player in migraine pathophysiology, CGRP-R
signaling was recognized as a potential therapeutic target, leading to the development of
small-molecule antagonists and mAbs that target either CGRP or CGRP-R [2, 23, 26]. By
inhibiting the release of pro-inflammatory
molecules within the trigeminal ganglion and/
or the dura and, therefore, reducing peripheral
sensitization, CGRP mAbs might indirectly
diminish central sensitization, reducing allostatic load and contributing to migraine
regression.
Development of CGRP Antagonists
Several therapeutics are used to treat migraine:
acute treatment includes nonsteroidal anti-inflammatory drugs and oral serotonin (5-hydroxytryptamine receptor 1B/1D) agonists
known as triptans [15], whereas drugs such as
anticonvulsants, antidepressants, antihypertensives, and botulinum toxins are used for
migraine prevention [78]. Many of these drugs,
which were not designed specifically for
migraine, can have multiple side effects [15]
and have poorly understood mechanisms of
action [79]. Furthermore, poor adherence and
frequent treatment-switching limit the effective
use of these medications [17–20].
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Until recently, first-line treatment for
migraine focused on the relief of acute pain
with triptans [80]. Triptans may provide effective pain relief during acute migraine; however,
a substantial proportion of patients remain
unresponsive [26]. Triptans act to constrict
cerebral blood vessels and to inhibit activation
of peripheral nociceptors on trigeminal afferents to reduce CGRP release [80–82]. In clinical
trials, it was shown that plasma CGRP levels
were reduced in patients whose migraine pain
subsided following treatment with sumatriptan,
but not in those who did not experience pain
relief [31]. CGRP levels also correlated positively
with pain intensity [31].
Most migraine preventives inhibit fast
synaptic transmission, whereas drugs targeting
neuropeptide pathways such as CGRP modulate
neuronal activity [46]. CGRP release may be
initiated by a Ca2?-dependent process involving
soluble N-ethylamide-sensitive factor attachment protein receptor (SNARE), which promotes vesicle docking and membrane fusion or,
alternatively, by a Ca2?- and SNARE-independent process [83]. Although triptans may inhibit Ca2? signaling and although botulinum
toxin type A prevents vesicular fusion through
cleavage of the SNARE protein SNAP-25, CGRP
release at the proximal axon of sensory neurons
independent of these mechanisms remains
unaffected [83]. This may explain why some
patients with migraine do not respond to these
therapies and supports the use of agents that
block CGRP-R signaling rather than CGRP
release.
Consequently, the ‘gepants’ were developed;
these are mostly oral, small-molecule CGRP-R
antagonists [84], six of which have been studied
clinically for the treatment of acute migraine:
olcegepant, telcagepant, MK-3207, BI 44370 TA,
rimegepant, and ubrogepant [85]. A seventh
gepant, atogepant, is in development for EM
prevention [85]. Gepants do not directly cause
vasoconstriction [86, 87], lending further
weight to the argument that migraine is not
purely a vascular disorder [26]. In clinical trials,
the first-generation gepant, telcagepant,
demonstrated efficacy for the treatment of acute
migraine compared with placebo and triptans
[88, 89]. However, liver toxicity limited its use
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as a preventive treatment. Other first-generation gepants (olcegepant, MK-3207, and BI
44370 TA) also showed promising results in
clinical trials [90–92], but were discontinued
owing to liver toxicity and to difficulties in
developing oral formulations [85]. Elevated
aminotransferase levels were attributable to offtarget effects by a toxic metabolite not produced by second-generation gepants [84, 93],
unleashing the potential of these agents as
preventive treatments for migraine. Ubrogepant
has recently been approved in the USA for the
acute treatment of migraine with or without
aura in adults [94], based on positive results
from Phase 3 studies, including a recent trial in
which significantly more patients taking ubrogepant were symptom-free 2 h after taking the
drug compared with patients taking placebo
(21.2% vs. 11.8%, respectively, p \ 0.001) [95].
The efficacy of rimegepant has been demonstrated in Phase 3 clinical trials in acute
migraine, with patients experiencing freedom
from pain at 2 h after dosing, sustained pain
relief for up to 48 h, and a reduction in associated symptoms such as photophobia and nausea [84, 96]. A further Phase 3 trial reported
results with a new formulation of rimegepant as
an orally disintegrating tablet (ODT), which was
superior to placebo when comparing proportions of patients free from pain and bothersome
symptoms 2 h post dose (21% vs. 11%, respectively, p \ 0.0001) [97]. Rimegepant ODT was
recently approved by the US Food and Drug
Administration (FDA) for the acute treatment of
migraine with or without aura in adults [98].
Two gepants remain in development: atogepant and zavegepant (formerly known as
vazegepant). Atogepant is the only gepant with
positive Phase 3 trial data for migraine prevention, with statistically significant reductions in
monthly headaches from baseline versus placebo (least squares mean differences: - 0.7
to - 1.4 days; p \ 0.05) and no reported signal
for hepatotoxicity [99, 100].
Positron emission tomography has shown
central CGRP-R occupancy by gepants (telcagepant) is not required for their therapeutic effect
in migraine, suggesting that large molecules
such as mAbs, which cross the BBB very inefficiently, are a viable option [101]. Areas of the
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hypothalamus, pituitary, and circumventricular
organs, such as the area postrema, are outside of
the BBB, and so are accessible to mAbs. Despite
their efficacy, early issues with tolerability of
gepants drove the search for alternative agents
with improved safety profiles, with a focus on
mAbs [26].
Anti-CGRP and Anti-CGRP-R Monoclonal
Antibodies
Therapeutic mAbs are highly selective for their
target molecule, binding a single epitope with
high affinity [26, 102] and not binding to other
antibodies or targets. This largely overcomes the
problem of off-target effects and toxicities
associated with small-molecule drugs and their
metabolites [26]. Therapeutic mAbs are used to
treat several diseases, including cancer and
autoimmune disorders [103]. They can trigger
target cell destruction, as in some types of cancer treatment where the objective is to stimulate
the patient’s immune system to attack the
cancer cells [104]. Other types of mAb do not
cause cell destruction, but instead bind to either
a ligand or a receptor, modifying cell signaling
pathways [104]; mAbs targeting CGRP-R signaling belong to this group. To reduce the
likelihood of an immune reaction to therapeutic antibodies, which is characteristic of antibodies generated in mice, antibody engineering
techniques have allowed the development of
chimeric, humanized, or fully human mAbs
[104].
mAbs targeting CGRP-R signaling are well
suited for migraine prevention, not only
because they target a pathway relevant to the
disease, but also because they require infrequent
administration relative to small-molecule drugs
[26]. As only a small proportion of any circulating mAb will typically reach the CNS [105],
targets within the CGRP-R signaling pathway
are likely to be peripheral (vasculature, dura, or
trigeminal ganglion) [106]. For CGRP-R signaling, one antibody reversibly targeting the
CGRP-R, where it occupies the CGRP ligandbinding site (erenumab-aooe [26, 107]), and
three targeting the CGRP ligand (fremanezumab-vfrm, galcanezumab-gnlm, and
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eptinezumab-jjmr) have been approved by the
FDA for migraine prevention (Table 1, Fig. 6)
[108]. Although many trials are ongoing, thus
far the evidence for the clinical efficacy and
tolerability profile of erenumab-aooe has been
most comprehensively reported. Anti-CGRP-R
signaling mAbs are efficacious in EM and CM in
clinical trials of up to 6 months’ duration
(Table 2) and are generally well tolerated. Erenumab-aooe has also been shown to be effective
and well tolerated longer term in both EM and
CM. In a 52-week open-label extension study in
patients with CM who continued treatment
after a 12-week double-blind period, treatment
with erenumab-aooe (70 mg or 140 mg once
monthly) was associated with changes in
monthly migraine days (MMD; mean [95%
confidence interval, CI]) from parent study
baseline of - 9.3 [- 10.0 to - 8.6] at week 52;
MMD were reduced to 8.8 from 18.1 at parent
study baseline. At week 52, respective reductions in MMD of C 50%, C 75%, or 100% from
parent-study baseline were observed in 59.0%,
33.2%, and 8.9% of patients still on study [109].
In an analysis of 5-year data from patients with
EM who continued open-label treatment following a 12-week double-blind period, treatment with erenumab-aooe (70 mg or 140 mg
once monthly) was associated, on average, with
5.3 fewer MMD at year 5, an average reduction
of 62.3% from baseline. Moreover, reductions in
MMD of C 50%, C 75%, or 100% at 5 years,
based on the last 4-week period of assessment,
were observed in 71.0%, 47.1%, and 35.5% of
patients, respectively [110]. Notably, erenumabaooe is efficacious in patients with EM in whom
multiple preventive treatments have been
unsuccessful (LIBERTY trial) [17], a patient
population under investigation by others
(FOCUS and CONQUER trials; patients with CM
or EM). In the LIBERTY trial, which included
patients with EM in whom two to four previous
preventive treatments had been unsuccessful,
30% of patients treated with erenumab-aooe
140 mg had C 50% reduction from baseline in
mean number of MMD at week 12 compared
with 14% of patients in the placebo group (odds
ratio [OR] [95% CI]: 2.7 [1.4–5.2]; p = 0.002)
[17]. Post hoc analyses of pivotal, double-blind,
placebo-controlled trials of erenumab-aooe in
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Table 1 FDA-approved anti-CGRP and anti-CGRP-R mAb characteristics
Feature

Erenumab-aooe [116]

Fremanezumab- Galcanezumab-gnlm [118] Eptinezumab-jjmr
vfrm [117]
[118]

Target

CGRP-R

CGRP ligand

CGRP ligand

CGRP ligand

Source

Fully human

Humanized

Humanized

Humanized

Isotype

IgG2

IgG2

IgG4

IgG1

Half-life

28 days [152]

31 days

25–30 days [152]

27 days

Glycosylation

Glycosylated

Both

No information available

No information available

Formulation

Tris buffer or acetate
buffer, and sorbitol or a
suitable substitute

L-histidine,
sucrose, PS80,
EDTA

L-histidine, hydrochloride
monohydrate, NaCl,
PS80, and water

L-histidine, L-histidine
hydrochloride
monohydrate, PS80,
sorbitol, and water

Viscosity

No information available

High

No information available

No information available

Administration
route

Subcutaneous

Subcutaneous

Subcutaneous

Intravenous

Administration
dose and
frequencya

70 mg, 140 mg

225 mg, QM

QM

675 mg, Q3M

240 mg initial dose then
120 mg QM

100 mg Q3M; some
patients may beneﬁt
from 300 mg Q3M

Adverse events

Injection-site reactions,
Injection-site
hypersensitivity reactions
reactions
(rash, swelling/edema,
(pain,
urticaria), constipation,
induration,
cramps/muscle spasms,
erythema,
pruritus
pruritus, rash)

Injection-site pain,
injection-site reactions,
vertigo, constipation,
pruritus, hypersensitivity
reactions (rash, urticaria,
dyspnea)

Hypersensitivity
reactions,
(angioedema, urticaria,
facial ﬂushing, rash)

CGRP calcitonin gene-related peptide, CGRP-R CGRP receptor, EDTA ethylenediaminetetraacetic acid, FDA US Food
and Drug Administration, IgG immunoglobulin G, mAb monoclonal antibody, PS polysorbate, Q3M every 3 months, QM
monthly
a
Doses and frequencies studied in registrational trials
patients with CM or EM are consistent with
these findings. Thus, 41% of patients with CM
in whom two or more prior preventive medications failed had C 50% reduction from baseline in mean number of MMD at 12 weeks when
treated with erenumab-aooe 140 mg compared
with 14% of patients receiving placebo (OR
[95% CI]: 4.2 [2.2–7.9]) [111]. Similarly, in
patients with EM in whom two or more prior
preventive medications failed, 36% of patients
treated with erenumab-aooe 140 mg had C 50%
reduction from baseline in mean number of
MMD (averaged over months 4 to 6) compared

with 11% of patients in the placebo group (OR
[95% CI]: 4.5 [1.7–12.4]) [112].
Results from a postmarketing study in 78
patients with EM and CM demonstrated erenumab-aooe (70 mg) to be highly effective and
well tolerated. In the EM patient group, a
reduction of 3.8 MMD was reported at 4 weeks
compared with baseline; in the CM patient
group, reductions of 12.2 and 15.0 MMD from
baseline were reported at 4 and 8 weeks,
respectively [113]. Furthermore, in a real-world
cohort of 65 individuals with severe migraine, a
reduction in MMD of C 50% was commonly
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Fig. 6 mAbs targeting CGRP or CGRP-R. CGRP-R
signaling may be reduced by mAbs that target either
CGRP or the CGRP-R. Although the CGRP-R is depicted
as a CLR-RAMP1 complex, it is not known if all CGRP
binding sites are formed by this complex. The CGRPresponsive receptor AMY1 has been found in the

trigeminal ganglion and brainstem, although a role of
AMY1 in migraine has not been conﬁrmed [50]. AMY
amylin receptor, CGRP calcitonin gene-related peptide,
CGRP-R CGRP receptor, CLR calcitonin-like receptor,
mAb monoclonal antibody, RAMP receptor activitymodifying protein

observed in 40–50% of individuals within different patient subgroups when treated with
erenumab-aooe. The cohort included patients
who would have been excluded from randomized controlled trials (i.e., those with more
chronic, frequent, severe, and refractory
migraine). For example, subgroups included
patients with CM of duration [ 10 years,
patients in whom [ 3 prophylactic medications
had failed, and patients scoring [ 60 on the sixitem Headache Impact Test [114].
Initial results (6 months) from a 1-year openlabel extension trial in 312 patients treated with
fremanezumab have also been reported.
Patients with EM taking monthly doses of fremanezumab experienced reductions in MMD
from 8.9 at baseline to 5.3 at 12 weeks and 4.0 at
6 months; patients on quarterly doses reported
decreases in MMD from 9.2 at baseline to 5.3 at
12 weeks and 4.2 at 6 months. Patients with CM
taking monthly doses of fremanezumab reported a decrease in MMD from 16.2 at baseline to
11.4 at 12 weeks and 8.3 at 6 months; patients
on quarterly doses experienced reductions in
MMD from 16.4 at baseline to 11.9 at 12 weeks
and 9.9 at 6 months [115].

Overall, mAbs have long elimination halflives, approximately 27–31 days for the mAbs
approved for the treatment of migraine
[116–118]. Physiological antibody concentrations are maintained, at least in part, by the
neonatal fragment crystallizable receptor,
which protects mAbs and other immunoglobulin G molecules from lysosomal degradation,
providing a salvage pathway that returns
approximately two-thirds of immunoglobulin
antibodies to the cell surface, the remainder
being degraded [119].
Although the immunogenic potential of
therapeutic antibodies is reduced by humanization, erenumab-aooe is the only fully human
antibody [26]. Further differentiating erenumab-aooe from the ligand-targeted mAbs is the
fact that those are CGRP-release dependent,
whereas receptor-targeted strategies are release
independent. It may be that, for migraine prevention, receptor-targeted strategies will provide a more sustained modulation of CGRP-R
signaling than ‘waiting’ for ligand release to
drive a feed-forward cycle.
CGRP expression is increased in RAMP1-deficient mice [120]. Conversely, CGRP-R
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Table 2 Efﬁcacy of FDA-approved mAbs in clinical trials for prevention of migraine
Name

Dose

Primary endpoint

Efﬁcacy outcome, mean change

Monthly migraine days (change from
baseline to months 4 through 6)

Active (n = 312) - 3.2 (SE 0.2)
days; p \ 0.001

Erenumab-aooe
STRIVE
[135]
(EM)

70 mg SC QM for
24 weeks
140 mg SC QM for
24 weeks

Active (n = 318) - 3.7 (SE 0.2)
days; p \ 0.001
Placebo (n = 316) - 1.8 (SE 0.2)
days

ARISE
[136]
(EM)

70 mg SC QM for
12 weeks

Phase 2 in
EM
[153]

7 mg SC QM for
12 weeks

Monthly migraine days (change from
baseline in the last 4 weeks of the trial)

Active (n = 282) - 2.9 (SE 0.2)
days; p \ 0.001
Placebo (n = 288) - 1.8 (SE 0.2)
days

Monthly migraine days (change from
baseline in the last 4 weeks of the trial)

Active 7 mg (n = 107) - 2.2
(SE 0.4) days; p = NS

21 mg SC QM for
12 weeks

Active 21 mg (n = 102) - 2.4
(SE 0.4) days; p = NS

70 mg SC QM for
12 weeks

Active 70 mg (n = 104) - 3.4
(SE 0.4) days; p = 0.021
Placebo (n = 153) - 2.3 (SE 0.3)
days

Phase 2 in
CM
[154]

70 mg SC QM for
12 weeks
140 mg SC QM for
12 weeks

Monthly migraine days

Active 70 mg (n = 191) - 6.6
(SE 0.4) days; p \ 0.0001
(change from baseline in the last 4 weeks of
the trial)
Active 140 mg (n = 190) - 6.6
(SE 0.4) days; p \ 0.0001
Placebo (n = 286) - 4.2 (SE 0.4)
days

Fremanezumab-vfrm
Phase 3 in
EM
[155]

225 mg SC QM for
12 weeks
675 mg SC Q3M for
12 weeks

Monthly migraine days (change during the Active (n = 287) - 3.7 (95%
12-week trial period, after ﬁrst dose)
CI - 4.15 to - 3.18) days;
p \ 0.001
Active (n = 288) - 3.4 (95%
CI - 3.94 to - 2.96) days;
p \ 0.001
Placebo (n = 290) - 2.2 (95%
CI - 2.68 to - 1.71) days
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Table 2 continued
Name

Dose

Primary endpoint

Phase 3 in
CM
[156]

675 mg SC at baseline
and 225 mg SC QM
for 12 weeks

Monthly migraine days (change during the Active 675 mg ? 225 mg
12-week trial period, after ﬁrst dose)
(n = 375) - 4.6 (SE 0.3) days;
p \ 0.001

675 mg SC Q3M for
12 weeks

Efﬁcacy outcome, mean change

Active 675 mg (n = 375) - 4.3
(SE 0.3) days; p \ 0.001
Placebo (n = 371) - 2.5 (SE 0.3)
days

Galcanezumab-gnlm
EVOLVE1 [157]
(EM)

120 mg SC QM for
6 months

EVOLVE2 [158]
(EM)

120 mg SC QM for
6 months

REGAIN
[159]

120 mg SC QM for
6 months

Monthly migraine days (change from
baseline during the treatment period)

Active (n = 210) - 4.7 (error
NR) days; p \ 0.001
Placebo (n = 425) - 2.8 (error
NR) days

Monthly migraine days (change from
baseline during the treatment period)

Active (n = 231) - 4.3 (SE 0.3)
days; p \ 0.001
Placebo (n = 461) - 2.3 (SE 0.2)
days

(CM)

Monthly migraine days (change from
Active (n = 273) - 4.8 (SE 0.4)
days; p \ 0.001
baseline during the 3-month double-blind
treatment period)
Placebo (n = 538) - 2.7 (SE 0.4)
days

Eptinezumab-jjmr
PROMISE- 30 mg IV Q3M for up to Monthly migraine days (change from
1 [142]
four administrations
baseline during weeks 1–12)
(EM)

100 mg IV Q3M for up
to four administrations
300 mg IV Q3M for up
to four administrations

Active 30 mg (n = 223) - 4.0
(95% CI - 4.41 to - 3.61)
days; p = 0.0046a
Active 100 mg (n = 221) - 3.9
(95% CI - 4.28 to - 3.47)
days; p = 0.0182
Active 300 mg (n = 222) - 4.3
(95% CI - 4.70 to - 3.90)
days; p = 0.0001
Placebo (n = 222) - 3.2 (95%
CI - 3.60 to - 2.79) days
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Table 2 continued
Name

Dose

Primary endpoint

Efﬁcacy outcome, mean change

PROMISE- 100 mg IV Q3M for two Monthly migraine days (change from
2 [143]
administrations
baseline during weeks 1–12)

Active 100 mg (n = 356) - 7.7
(error NR) days; p \ 0.0001

(CM)

Active 300 mg (n = 350) - 8.2
(error NR) days; p \ 0.0001

300 mg IV Q3M for two
administrations

Placebo (n = 366) - 5.6 (error
NR) days
CI conﬁdence interval, CM chronic migraine, EM episodic migraine, FDA US Food and Drug Administration, IV
intravenous, mAb monoclonal antibody, NR not reported, NS nonsigniﬁcant, Q3M every 3 months, QM monthly, SC
subcutaneous, SE standard error
a
Not statistically signiﬁcant per hierarchy testing
CM deﬁned as C 15 days/month in all trials; EM deﬁned as 4–14 migraine days/month except in fremanezumab-vfrm
trials in which it was deﬁned as \ 15 days/month

expression is elevated in a-CGRP knockout mice
[121]. Thus, upregulation of CGRP-R or AMY1
expression might be anticipated in response to
chronic ligand depletion or receptor blockade
in humans. If this occurs and receptor density
increases, the observed efficacy of CGRP-R-targeted mAbs may increase over time because
receptors remain saturated. The binding of
antibodies to CGRP or to CGRP-R may result in
the formation of distinct receptor conformations that signal through unique pathways
(novel signaling bias), although this requires
further investigation [122].
CGRP Receptor Signaling Monoclonal
Antibody Safety
Given the widespread role of CGRP, it might be
expected that CGRP-R signaling blockade could
result in safety concerns; however, the clinical
trial data for anti-CGRP and anti-CGRP-R mAbs
showed only mild drug-related adverse events,
including injection-site reactions, hypersensitivity reactions (such as erythema or pruritus),
and constipation (Table 1) [116–118]. Analysis
of 5-year data from patients with EM participating in an open-label extension after a
12-week double-blind phase showed no new
safety signals and no increase in the incidence
of adverse events or of serious adverse events

with longer-term erenumab-aooe use compared
with the double-blind treatment phase [110]. A
pooled analysis of four double-blind randomized trials and their extension studies in 2375
patients who received at least one dose of erenumab-aooe (70 mg or 140 mg; cumulative
exposure, 2641 patient-years) found that erenumab-aooe had a favorable and stable adverse
event profile for over 3 years in patients with
EM or CM. Exposure-adjusted adverse event
rates with erenumab-aooe were similar to placebo during the double-blind phase, except
injection site-reactions (17.1 vs. 10.8 per 100
patient-years), constipation (7.0 vs. 3.8 per 100
patient-years), and muscle spasm (2.3 vs. 1.2 per
100 patient-years). Adverse events reported
during the long-term extensions were similar to
those in the double-blind treatment phase, and
rates of injection-site reactions, constipation,
and muscle spasm were lower [123].
Furthermore, studies have explored any
potential cardiovascular impact of erenumabaooe. No differences between erenumab-aooe
and placebo were observed for any endpoint
during treadmill testing or the 12-week safety
follow-up in a clinical trial of patients with
ischemic cardiovascular disease [124], nor were
any differences in arterial blood pressure
observed in healthy volunteers in a placebocontrolled study of concomitant administration
of erenumab-aooe and sumatriptan [125]. The
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cardiovascular, cerebrovascular, and peripheral
vascular safety of erenumab-aooe in patients
with CM or EM was investigated in a pooled
analysis of four double-blind, placebo-controlled studies and their open-label extensions.
A total of 2443 patients were included; of these,
1043 received placebo, 893 erenumab-aooe
70 mg, and 507 erenumab-aooe 140 mg. The
incidence of vascular adverse events was similar
between placebo and erenumab-aooe over
12 weeks, and the emergence of adverse events
did not increase over time (up to 256 weeks)
[126]. The lack of cardiovascular adverse effects
associated with CGRP-R blockade suggests
redundancy in the CGRP-R system (both CGRP
and amylin bind to AMY1 with high affinity) or
compensatory
vasodilatory
mechanisms
[124, 127, 128]. However, the potential for cardiovascular adverse effects following CGRP
ligand blockade cannot be ruled out based on
results from these studies alone. Development
of hypertension and worsening of pre-existing
hypertension have been reported following the
use of erenumab-aooe in the postmarketing
setting. Many of these patients had pre-existing
hypertension or risk factors for hypertension. In
most cases, the onset or worsening of hypertension was reported after the first dose and
were more frequently reported within seven
days of dose administration although they
could occur at any time during treatment. There
were cases of hypertension requiring pharmacological treatment and, in some cases, hospitalization. Per the Aimovig (erenumab-aooe) US
Prescribing Information, patients treated with
erenumab-aooe should be monitored for newonset or worsening of pre-existing hypertension
and treatment discontinuation considered if an
alternative etiology cannot be established [116].
Approved anti-CGRP-R signaling mAbs are
administered by subcutaneous injection, via
autoinjectors
(erenumab-aooe
and
galcanezumab-gnlm), prefilled syringe (fremanezumab-vfrm), or intravenous infusion
(eptinezumab-jjmr) [116–118, 129]. Injectionsite reactions after subcutaneous administration
are common, resulting in localized pain, pruritus, and erythema [130], and rates appear to be
higher with fremanezumab-vfrm and galcanezumab-gnlm than with erenumab-aooe,
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with 26–30%, 6–21%, and 3–6% of patients,
respectively, reporting injection-site pain in
Phase 3 trials [116–118]. Fewer injection-site
reactions with erenumab-aooe, together with
the availability of an autoinjector, may have a
positive effect on adherence, although this will
need confirmation in dedicated studies. Reactions may be linked to the immunogenicity of
the drug or excipients such as polysorbate-related activation of complement or reactive
degradation products [131]. Additionally, drug
volume, viscosity, sugar concentration, pH, and
having L-histidine as an excipient may all contribute to the variability of injection-site
reactions.
CGRP may have a role in regulating uteroplacental blood flow, other vascular adaptations
during pregnancy, and relaxation of uterine
smooth muscle, resulting in potential complications in pregnancy [132]. However, to date,
no adverse effects have been observed on pregnancy in rats and rabbits (fremanezumab-vfrm,
galcanezumab-gnlm, and eptinezumab-jjmr), or
monkeys (erenumab-aooe) following antiCGRP-R signaling mAb administration at doses
higher than used clinically [116–118, 129].
The gastrointestinal tract is highly innervated by enteric neurons expressing CGRP,
which is thought to affect intestinal blood flow,
smooth muscle relaxation, and slow wave
amplitude [133, 134]. Constipation was reported as an adverse event in erenumab-aooe clinical trials in 1–3% of patients [116, 135], and
constipation rates did not increase with longerterm treatment (B 5 years) [110]. Suspected
cases of constipation with serious complications
have been observed in a postmarketing setting,
although the incidence has not been reported
[116]. For context, no cases of serious constipation were reported with erenumab-aooe during Phase 3 trials, which accumulated over 300
person-years [135, 136]. An incidence of serious
constipation in people initiating migraine
treatment of 0.63 per 100 person-years has been
reported [137]. It is important to monitor and to
manage patients receiving erenumab-aooe as
clinically appropriate if cases of constipation
with serious complications occur [116],
although these cases are likely to be uncommon. Constipation is also now listed as a side
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effect of galcanezumab [138], implying that
constipation may be a class effect. This side
effect is consistent with preclinical studies
showing that CGRP causes diarrhea in mice
[139]. None of the approved CGRP-R and CGRP
ligand mAbs are contraindicated in patients
with impaired hepatic or renal function, and
such impairment is not expected to alter the
pharmacokinetics of the drugs [116–118]. The
lack of any hepatotoxic effects in this drug class
is in sharp contrast to those effects observed
with repeated exposure to certain early gepants
[23].
A known phenomenon of therapeutic antibodies is the development of neutralizing antibodies [140]. Pooled data from erenumab-aooe
clinical trials showed that only a small proportion of patients developed anti-erenumab-aooebinding antibodies (70 mg, 6.3% [56/884];
140 mg, 2.6% [13/504]), only three of whom
had neutralizing antibodies. By the end of the
study, [ 50% of patients who developed binding antibodies reverted to negative status and
the mean change in MMD did not appreciably
differ between patients who did or did not
develop anti-erenumab-aooe-binding antibodies [141]. Furthermore, anti-erenumab-aooebinding antibodies had no impact on safety,
and the concentrations of erenumab-aooe
overlapped with those of patients who were
antibody negative [141]. In placebo-controlled
studies of galcanezumab-gnlm, 4.8% of patients
(33/688) developed anti-drug antibodies [118];
in a 12-month open-label trial, 12.5% of
patients (16/128) developed anti-drug antibodies, most of which were neutralizing [118]. For
fremanezumab-vfrm, placebo-controlled trials
revealed that 0.4% of patients (6/1701) developed anti-drug antibodies, while in an ongoing
open-label study, 1.6% of patients (30/1888)
developed anti-drug antibodies [117]. In
patients receiving eptinezumab 100 mg or
300 mg every 3 months in Phase 3 trials (PROMISE-1 and PROMISE-2), the incidence of antieptinezumab antibodies was 20.6% (92/447) in
PROMISE-1 (up to 56 weeks) and 18.3% (129/
706) in PROMISE-2 (up to 32 weeks)
[129, 142, 143]. The impact of neutralizing
antibody development on clinical efficacy has
not been shown.
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Drug-drug interactions are unlikely to occur
between mAbs and other medications, because
mAbs are degraded into peptides or amino
acids, although the potential for issues arising
with concomitant treatment with mAbs and
other preventive therapies for migraine is not
known. Additionally, it is unknown if there are
issues with switching between receptor- and
ligand-binding CGRP mAbs [140].

FUTURE DIRECTIONS
FOR MONOCLONAL ANTIBODIES
FOR MIGRAINE
Migraine presents with an abundance of nonpain signs and symptoms. Patients receiving
anti-CGRP-R signaling treatments commonly
experience improvements in other neurological
abnormalities of migraine, including reduced
sensory aura and improved cognition. However,
no longitudinal data are available to indicate
the long-term effects (e.g., rebound pain, disease modification) of anti-CGRP-R signaling
mAbs [128]. Since the introduction of these
agents, patients increasingly mention that the
‘brain fog’ associated with migraine has lifted,
with many remarking that this change is more
noticeable between than during attacks.
Anti-CGRP-R signaling mAbs are likely to be
used effectively in combination with other
migraine-preventive treatments, which have
different molecular targets. Anti-CGRP-R signaling mAbs might be expected to decrease
signaling between attacks, protecting against
trigeminal nerve hypersensitivity, although
longitudinal studies are required to demonstrate this. Additionally, although there is some
evidence that the integration of anti-CGRP-R
signaling mAbs may reduce the use of acute
migraine treatments [144], further research is
needed to evaluate the efficacy and safety of
these mAbs in combination with other standard-of-care medications. Further to this, a post
hoc analysis has been performed on erenumabaooe Phase 2 trial data in patients with CM and
medication overuse in whom preventive treatment had previously failed. Erenumab-aooe
reduced the number of MMD and moderatesevere headache days, reduced the use of acute
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migraine medication, and increased the proportion of patients achieving nonmedication
overuse status versus placebo [144]. Moreover,
in a Phase 3 trial, fremanezumab-vfrm reduced
the number of days of acute headache medication use over a 12-week period versus placebo in
patients with medication overuse at baseline
[145]. It will also be necessary to assess antiCGRP-R signaling mAbs in children, adolescents, during pregnancy, and in similar headache conditions [146].
It has been shown that lower injection frequency and increased efficacy are key drivers of
patient adherence [147]. Efficacious mAbs with
relatively infrequent dosing may therefore be
well received by some patients compared with
small molecules or botulinum toxin type A,
based on their frequency of administration or
number of injections per dose (31–39 injections/dose for botulinum toxin type A) [148].
Further studies on adherence in a real-world
setting are needed.
The involvement of other receptors and
pathways (such as AMY1, the pituitary adenylate cyclase-activating peptide system, the
serotonin-5-HT1F receptor, purinergic receptors,
hyperpolarization-activated cyclic nucleotidegated channels, adenosine triphosphate-sensitive potassium channels, and the glutaminergic
system [149]) and the potential for treatments
that work synergistically (such as concomitant
small-molecule CGRP-R antagonists and CGRPbased mAbs [150]) could also be assessed.
Approved anti-CGRP-R signaling mAbs are
effective for approximately 50% of patients
[116–118, 129] and may encourage future
development of centrally and peripherally acting CGRP drugs. Combining medications that
have peripheral effects with treatments that
target central processes may be a good combination therapy approach for migraine control.

CONCLUSION
There is an unmet need for preventive migraine
therapies, and targeting CGRP-R signaling offers
much potential. Several mAbs that target the
CGRP-R or ligand are approved by the FDA and
have proven to be efficacious and well tolerated
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in pivotal clinical trials. These migraine-specific
treatments may help patients who are hypervigilant and to reduce allostatic load. Further
evidence is required to determine if there are
any real-world differences between ligand- and
receptor-targeted therapies and to optimize
their use. It will be interesting to discover to
what degree these therapies are disease-modifying and, if so, whether this results from an
ability to modulate allostatic load.
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